Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 5:14:1330592.
doi: 10.3389/fonc.2024.1330592. eCollection 2024.

The potential of circHIPK3 as a biomarker in chronic myeloid leukemia

Eduardo Wandame Gomez  1   2 , Laura Berti De Paula  1 , Rafael Diogo Weimer  1 , Alessandra Helena da Silva Hellwig  2 , Grazielle Motta Rodrigues  2 , Ana Paula Alegretti  2 , Jarbas Rodrigues de Oliveira  1
Affiliations
Review

The potential of circHIPK3 as a biomarker in chronic myeloid leukemia

Eduardo Wandame Gomez et al. Front Oncol. .

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by leukocytosis and left shift. The primary molecular alteration is the BCR::ABL1, chimeric oncoprotein with tyrosine kinase activity, responsible for the initial oncogenesis of the disease. Therapy of CML was revolutionized with the advent of tyrosine kinase inhibitors, but it is still not considered curative and may present resistance and serious adverse effects. Discoveries in CML inaugurated a new era in cancer treatment and despite all the advances, a new biomarker is needed to detect resistance and adverse effects. Circular RNAs (circRNAs) are a special type of non-coding RNA formed through a process called backsplicing. The majority of circRNAs are derived from protein-coding genes. CircHIPK3 is formed from the second exon of the HIPK3 gene and has been found in various pathologies, including different types of cancer. New approaches have demonstrated the potential of circular RNAs in cancer research, and circHIPK3 has shown promising results. It is often associated with cellular regulatory pathways, suggesting an important role in the molecular dynamics of tumors. The identification of biomarkers is an important tool for therapeutic improvement; thus we review the role of circHIPK3 and its potential as a biomarker in CML.

Keywords: CircHIPK3; biomarker; chronic myeloid leukemia; circRNA; ncRNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Scheme of circHIPK3 production.
Figure 2
Figure 2
Dualistic mechanisms of circHIPK3 action in cancer.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. de Alves RCS. Análise de pacientes com leucemia mieloide crônica com resistência primária ou secundária ao mesilato de imatinibe. Rev Bras Hematol E Hemoter. (2009) 31:166–77. doi: 10.1590/S1516-84842009005000053 - DOI
    1. Hochhaus A, Erben P, Ernst T, Mueller MC. Resistance to targeted therapy in chronic myelogenous leukemia. Semin Hematol. (2007) 44:15–24. doi: 10.1053/j.seminhematol.2006.12.002 - DOI - PubMed
    1. Saglio G, Sharf G, Almeida A, Bogdanovic A, Bombaci F, Čugurović J, et al. . Considerations for treatment-free remission in patients with chronic myeloid leukemia: A joint patient–physician perspective. Clin Lymphoma Myeloma Leukemia. (2018) 18:375–9. doi: 10.1016/j.clml.2018.04.005 - DOI - PubMed
    1. Cortes J, Perez-García JM, Llombart-Cussac A, Curigliano G, El Saghir NS, Cardoso F, et al. . Enhancing global access to cancer medicines. CA. Cancer J Clin. (2020) 70:105–24. doi: 10.3322/caac.21597 - DOI - PubMed
    1. Xu T, Wang M, Jiang L, Ma L, Wan L, Chen Q, et al. . CircRNAs in anticancer drug resistance: recent advances and future potential. Mol Cancer. (2020) 19:127. doi: 10.1186/s12943-020-01240-3 - DOI - PMC - PubMed